Cargando…

Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy

When confronted with non-psychotic mental disorders, pregnant women often refrain from using synthetic drugs and resort to herbal medicines such as St. John’s wort, California poppy, valerian, lavender, and hops. Nevertheless, these herbal medicines have not yet been officially approved in pregnancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiess, Deborah, Winker, Moritz, Dolder Behna, Alexandra, Gründemann, Carsten, Simões-Wüst, Ana Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259859/
https://www.ncbi.nlm.nih.gov/pubmed/35814220
http://dx.doi.org/10.3389/fphar.2022.882997
_version_ 1784741879488708608
author Spiess, Deborah
Winker, Moritz
Dolder Behna, Alexandra
Gründemann, Carsten
Simões-Wüst, Ana Paula
author_facet Spiess, Deborah
Winker, Moritz
Dolder Behna, Alexandra
Gründemann, Carsten
Simões-Wüst, Ana Paula
author_sort Spiess, Deborah
collection PubMed
description When confronted with non-psychotic mental disorders, pregnant women often refrain from using synthetic drugs and resort to herbal medicines such as St. John’s wort, California poppy, valerian, lavender, and hops. Nevertheless, these herbal medicines have not yet been officially approved in pregnancy due to lack of safety data. Using a variety of in vitro methods (determination of cytotoxicity, apoptosis induction, genotoxicity, effects on metabolic properties, and inhibition/induction of differentiation) in a commonly used placental cell line (BeWo b30), we were previously able to show that extracts from these plants are likely to be safe at the usual clinical doses. In the present work, we wanted to extend our safety assessment of these herbal medicines by 1) looking for possible effects on gene expression and 2) using the same in vitro methods to characterize effects of selected phytochemicals that might conceivably lead to safety issues. Proteomics results were promising, as none of the five extracts significantly affected protein expression by up- or down-regulation. Protopine (contained in California poppy), valerenic acid (in valerian), and linalool (in lavender) were inconspicuous in all experiments and showed no adverse effects. Hyperforin and hypericin (two constituents of St. John’s wort) and valtrate (typical for valerian) were the most obvious phytochemicals with respect to cytotoxic and apoptotic effects. A decrease in cell viability was evident with hypericin (≥1 µM) and valtrate (≥10 µM), whereas hyperforin (≥3 µM), hypericin (30 µM) and valtrate (≥10 µM) induced cell apoptosis. None of the tested phytochemicals resulted in genotoxic effects at concentrations of 0.1 and 1 µM and thus are not DNA damaging. No decrease in glucose consumption or lactate production was observed under the influence of the phytochemicals, except for valtrate (at all concentrations). No compound affected cell differentiation, except for hyperforin (≥1 µM), which had an inhibitory effect. This study suggests that extracts from St. John’s wort, California poppy, valerian, lavender, and hops are likely to be safe during pregnancy. High plasma concentrations of some relevant compounds—hyperforin and hypericin from St. John’s wort and valtrate from valerian—deserve special attention, however.
format Online
Article
Text
id pubmed-9259859
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92598592022-07-08 Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy Spiess, Deborah Winker, Moritz Dolder Behna, Alexandra Gründemann, Carsten Simões-Wüst, Ana Paula Front Pharmacol Pharmacology When confronted with non-psychotic mental disorders, pregnant women often refrain from using synthetic drugs and resort to herbal medicines such as St. John’s wort, California poppy, valerian, lavender, and hops. Nevertheless, these herbal medicines have not yet been officially approved in pregnancy due to lack of safety data. Using a variety of in vitro methods (determination of cytotoxicity, apoptosis induction, genotoxicity, effects on metabolic properties, and inhibition/induction of differentiation) in a commonly used placental cell line (BeWo b30), we were previously able to show that extracts from these plants are likely to be safe at the usual clinical doses. In the present work, we wanted to extend our safety assessment of these herbal medicines by 1) looking for possible effects on gene expression and 2) using the same in vitro methods to characterize effects of selected phytochemicals that might conceivably lead to safety issues. Proteomics results were promising, as none of the five extracts significantly affected protein expression by up- or down-regulation. Protopine (contained in California poppy), valerenic acid (in valerian), and linalool (in lavender) were inconspicuous in all experiments and showed no adverse effects. Hyperforin and hypericin (two constituents of St. John’s wort) and valtrate (typical for valerian) were the most obvious phytochemicals with respect to cytotoxic and apoptotic effects. A decrease in cell viability was evident with hypericin (≥1 µM) and valtrate (≥10 µM), whereas hyperforin (≥3 µM), hypericin (30 µM) and valtrate (≥10 µM) induced cell apoptosis. None of the tested phytochemicals resulted in genotoxic effects at concentrations of 0.1 and 1 µM and thus are not DNA damaging. No decrease in glucose consumption or lactate production was observed under the influence of the phytochemicals, except for valtrate (at all concentrations). No compound affected cell differentiation, except for hyperforin (≥1 µM), which had an inhibitory effect. This study suggests that extracts from St. John’s wort, California poppy, valerian, lavender, and hops are likely to be safe during pregnancy. High plasma concentrations of some relevant compounds—hyperforin and hypericin from St. John’s wort and valtrate from valerian—deserve special attention, however. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259859/ /pubmed/35814220 http://dx.doi.org/10.3389/fphar.2022.882997 Text en Copyright © 2022 Spiess, Winker, Dolder Behna, Gründemann and Simões-Wüst. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Spiess, Deborah
Winker, Moritz
Dolder Behna, Alexandra
Gründemann, Carsten
Simões-Wüst, Ana Paula
Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy
title Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy
title_full Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy
title_fullStr Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy
title_full_unstemmed Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy
title_short Advanced in Vitro Safety Assessment of Herbal Medicines for the Treatment of Non-Psychotic Mental Disorders in Pregnancy
title_sort advanced in vitro safety assessment of herbal medicines for the treatment of non-psychotic mental disorders in pregnancy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259859/
https://www.ncbi.nlm.nih.gov/pubmed/35814220
http://dx.doi.org/10.3389/fphar.2022.882997
work_keys_str_mv AT spiessdeborah advancedinvitrosafetyassessmentofherbalmedicinesforthetreatmentofnonpsychoticmentaldisordersinpregnancy
AT winkermoritz advancedinvitrosafetyassessmentofherbalmedicinesforthetreatmentofnonpsychoticmentaldisordersinpregnancy
AT dolderbehnaalexandra advancedinvitrosafetyassessmentofherbalmedicinesforthetreatmentofnonpsychoticmentaldisordersinpregnancy
AT grundemanncarsten advancedinvitrosafetyassessmentofherbalmedicinesforthetreatmentofnonpsychoticmentaldisordersinpregnancy
AT simoeswustanapaula advancedinvitrosafetyassessmentofherbalmedicinesforthetreatmentofnonpsychoticmentaldisordersinpregnancy